Search Results
Your search for The ASCO matches 21740 pages
Showing 21501 - 21550Study Sets Guidelines for Stem Cell Transplants in Older Patients with Myelodysplastic Syndromes
A new study by an international team of scientists provides the first statistically based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes (MDS), the most common blood disorders in people over 60 years of age, and frequently...
Among White Adolescents and Young Adults with Melanoma, Males Have Higher Mortality Than Females
Melanoma is the third most common cancer among adolescents and young adults, but few studies have explored the survival differences by sex in this population. A new study published in JAMA Dermatology sought to determine whether long-term survival varied between white male and female...
Study Reveals Abstracts with Financial Conflicts of Interest Have Higher Meeting Prominence, Better Peer Review Score
Beverly Moy, MD, Clinical Director of the Breast Oncology Program at Massachusetts General Hospital, and colleagues recently analyzed the relationship between declaration of financial conflicts of interest and "research prominence" for abstracts presented at American Society of Clinical Oncology...
Lugano 2013: Vitamin D Deficiency Associated with Worse Outcome in Elderly Patients with Aggressive B-cell Lymphoma Receiving R-CHOP or CHOP
Vitamin D deficiency recently was shown to be associated with worse outcome in patients with non-Hodgkin lymphoma. To determine whether such an association exists in patients with aggressive B-cell lymphoma, Jörg T. Bittenbring, of Saarland University Medical School, Germany, and colleagues in ...
BRAF Mutation Status May Have Effect on Benefit of Aspirin Use for Patients with Colorectal Cancer
In two large studies, the association between aspirin use and risk of colorectal cancer was affected by BRAF mutation status, with regular aspirin use associated with a lower risk of BRAF wild-type colorectal cancer but not with risk of BRAF-mutated cancer. The findings, published today in JAMA,...
Use of Advanced Treatment Technologies Increases among Men at Low Risk of Dying from Prostate Cancer
Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy (IMRT) and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these...
New Study Finds AICR Recommendations Cut Breast Cancer Risk
Postmenopausal women who follow at least five Recommendations for Cancer Prevention from the American Institute for Cancer Research (AICR) cut their risk of developing breast cancer by more than half, compared to those who meet none, suggests a new study that adds to previous research showing...
Researchers Identify and Map Signaling Pathway from EGFR to MCM7 Protein
Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point. A team led by scientists at The University of Texas MD Anderson Cancer Center reported the tie between...
Investigators Identify Promising Biomarker for Predicting HPV-related Oropharyngeal Cancer
Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, In their study, at least one in three individuals with oropharyngeal cancer had antibodies to HPV, compared to...
Deep Sequencing Accurately Predicts Prolonged Survival in Multiple Myeloma Patients
A study by the Spanish Myeloma Group comparing the prognostic value of traditional response criteria and minimal residual disease measurement in patients with multiple myeloma found that a sequencing-based method called LymphoSIGHT and multiparameter flow cytometry analysis both accurately...
Virus Combination Effective Against Temozolomide-resistant Glioblastoma Multiforme
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to new research published in Neuro-Oncology. Study lead author Peter A. Forsyth, MD, Chair of the Neuro-oncology Program at Moffitt ...
Screening Colonoscopy Associated with Increased Survival Duration and Rates for Patients with Colon Cancer
Patients with colon cancer identified on screening colonoscopy appear to have lower-stage disease on presentation and better outcomes independent of their staging, according to a report published online today in JAMA Surgery. Since their introduction in 2000, National Institutes of Health...
Mortality Appears to be Higher for Patients with Thicker Single Primary Melanomas than for Thicker Multiple Primary Melanomas
Although overall mortality rates due to single primary melanomas and multiple primary melanomas appear to be similar, relative mortality for thicker single primary melanomas appears to be greater than that for thicker multiple primary melanomas, according to a study by Anne Kricker, PhD, of the...
Observation Is Safe, Cost-saving Option for Patients with Low-risk Prostate Cancer
Many men with low-risk, localized prostate cancers can safely choose active surveillance or watchful waiting instead of undergoing immediate treatment and have better quality of life while reducing health-care costs, according to a study by researchers at Dana-Farber Cancer Institute and...
Investigational New Drug Application Filed for CFI-400945
Investigators from Princess Margaret Cancer Centre in Toronto and the University of California, Los Angeles, have submitted an Investigational New Drug (IND) application for CFI-400945, a novel drug candidate targeting the enzyme PLK4, which plays a crucial role in cell division. The news was...
Global Alliance Is Formed to Share Genomic Data
This month, an international group of over 70 research and health-care organizations, academic centers, and medical societies, including ASCO, signed a letter of intent to form a global alliance to make medicine more effective by consolidating the world’s databases of genomic information. The ...
ASCO 2013: Genomic Heterogeneity Can Lead to the Selection of ‘Incorrect’ Targeted Inhibitors
Genomic heterogeneity within tumors and among lesions varies widely, and “discordance among lesions could lead to the selection of the ‘incorrect’ targeted inhibitor,” according to David B. Solit, MD, of Memorial Sloan-Kettering Cancer Center, who spoke at the ASCO/American...
NCI Will No Longer Accept R01 and P01 Applications for Phase III Clinical Trials of Medical Interventions and Cancer Imaging Modalities
The National Cancer Institute (NCI) has announced that it will no longer accept investigator-initiated R01 and P01 applications that propose phase III clinical trials for cancer-related medical interventions or cancer imaging modalities. The policy change takes effect starting with the due date of...
FDA Approves New Silicone Gel-filled Breast Implant
The FDA recently approved the MemoryShape Breast Implant for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. The MemoryShape Breast Implants are manufactured by Mentor Worldwide LLC. The FDA’s approval is based on 6 years of data from 955 ...
Abnormalities in New Molecular Pathway May Increase Breast Cancer Risk
A new molecular pathway involving the gene ZNF365 has been identified, and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. “Genomic...
Osteoporosis Drug Stops Growth of Breast Cancer Cells in Tamoxifen-resistant Tumors
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a study presented at the Endocrine Society’s 95th Annual Meeting in San Francisco. The findings ...
Metabolic Molecule Drives Growth of High-grade Glioma
A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has identified an abnormal metabolic pathway that drives cancer cell growth in a particular glioblastoma...
Developmental Protein Plays Role in Spread of Cancer
A protein used by embryo cells during early development, and recently found in many different types of cancer, may serve as a switch regulating metastasis, according to researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center. The findings were ...
Trebananib plus Paclitaxel Significantly Delays Disease Progression in Patients with Recurrent Ovarian Cancer
In a phase III trial, treatment with the investigational agent trebananib plus paclitaxel resulted in a statistically significant improvement in progression-free survival in patients with recurrent ovarian cancer, according to Amgen. Trebananib is an investigational peptibody designed to inhibit...
FDA Approves Denosumab to Treat Giant Cell Tumor of the Bone
The U.S. Food and Drug Administration (FDA) today expanded the approved use of denosumab (Xgeva) to treat adults and some adolescents with giant cell tumor of the bone, a rare and usually noncancerous tumor. Denosumab, which was granted orphan product designation, was reviewed under the FDA’s ...
Newly Identified Markers May Predict Who Will Respond to Breast Cancer Prevention Therapy
Single nucleotide polymorphisms (SNPs) in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. ...
ASCO 2013: First Prospective Trial Shows Molecular Profiling Timely for Tailoring Therapy
A clinical trial has shown that patients and their physicians are eager to jump into the next generation of cancer care: analysis of an individual’s tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, were presented at the 2013 ASCO Annual Meeting...
ASCO 2013: Lung Cancer Mutations ALK and ROS1 Also Drive Colorectal Cancer
A study from the University of Colorado Cancer Center shows that the ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. Results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of...
Research Team Identifies Genetic Risk for Cancer in Breast Cells
An Indiana University cancer researcher and his Canadian collaborator have discovered how normal breast precursor cells may be genetically vulnerable to developing into cancer. David Gilley, PhD, Associate Professor of Medical and Molecular Genetics at the IU School of Medicine and a researcher at ...
ASCO 2013: Top Five Things Oncologists Need to Know about Cancer in Older Adults
A workforce shortage of geriatricians and other health professionals trained and certified in caring for older patients with cancer is colliding with the aging of the population and the increasing number of older Americans with cancer. After describing factors contributing to these dual challenges, ...
CMS Says It Lacks Authority to Roll Back Sequestration Cuts to Medicare Payments for Part B Cancer Drugs
According to a June 3 letter from the Centers for Medicare and Medicaid Services (CMS), there will be no reprieve in the 2% ($11.08 billion) reduction to Medicare providers and hospitals mandated by the federal budget sequestration. The letter by CMS Acting Administrator Marilyn Tavenner was in...
Radioimmunotherapy/Chemotherapy Combination Could Extend Survival in Some Patients with Advanced Lymphoma
A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy showed encouraging overall survival rates in some patients preparing for autologous bone marrow transplant, reported researchers at the 2013 Annual Meeting of the Society of...
Study Paves Way for Rational Drug Targeting of B-cell Lymphomas
A new study from Dana-Farber Cancer Institute may help clinicians and drug researchers choose the most promising genetic targets to attack in a common type of non-Hodgkin lymphoma. The report, published in the June 10 issue of Cancer Cellprovides a new, “big picture” view of an...
Sequential PET/MRI Predicts Chemotherapy’s Ability to Improve Survival in Patients with Advanced Breast Cancer
For patients with advanced breast cancer, positron-emission tomography (PET) and magnetic resonance imaging (MRI) can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, according to researchers presenting at the 2013...
Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half
A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...
ASCO 2013: Surveillance Sufficient Follow-up for Most Patients with Stage I Seminoma
Surveillance appears to be sufficient for men with stage I seminoma treated with orchiectomy, sparing patients from side effects of adjuvant radiation or chemotherapy. In a long-term study presented at the 2013 ASCO Annual Meeting (Abstract 4502), 99.5% of men followed by surveillance alone...
FDA Grants Orphan Drug Status for Novel Targeted Therapy for the Treatment of Rare Hematologic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Stemline Therapeutics' SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive hematologic malignancy for which there is no effective treatment. SL-401 also has Orphan Drug...
FDA Clears Multicenter Trial of Treatment for Chemotherapy-related Hair Loss
The FDA has approved initiation of a multicenter trial of the DigniCap System, a scalp-cooling device for chemotherapy-related hair loss. The trial is the second and final phase of study for the DigniCap System. A pilot study previously conducted by researchers at the University of California San...
Potential New Way to Suppress Tumor Growth Discovered
Researchers at the University of California, San Diego, School of Medicine, and University of Rochester Medical Center have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anticancer drugs. The findings were published in this...
Clinical Sequencing Technology Identifies New Targets in Diverse Cancers
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in...
DNA Sequencing Reveals Mucosal Melanoma's Genetic Fingerprint
Scientists have found a molecular "bullseye" for a rare form of melanoma, opening up opportunities for novel targeted treatment, according to new research published in the Journal of Pathology. Whole genome and whole exome sequencing carried out at Cancer Research UK’s Paterson Institute for ...
ASCO 2013: Novel Heat Shock Protein Inhibitor Effective in Combination with Docetaxel as Second-line Therapy for Advanced Lung Cancer
A large randomized phase II study, GALAXY-1, found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma...
ASCO 2013: More than 20% of African American Women Carry Inherited Mutations in at Least One Breast Cancer Susceptibility Gene
A genomic profiling study of African American women with breast cancer found that about one in five carries an inherited abnormality in at least 1 of 18 genes associated with breast cancer susceptibility. Such mutations were more prevalent among women with aggressive triple-negative breast cancer,...
ASCO 2013: Less Lymphedema with Axillary Radiotherapy than Node Dissection, but Comparable Disease Control
A European phase III clinical trial found that lymphedema was twice as common among women with sentinel lymph node–positive early breast cancer who had axillary lymph node dissection compared to those who had axillary radiotherapy. Overall and disease-free survival 5 years after treatment...
ASCO 2013: Weekly Paclitaxel Is Less Toxic but as Effective for Women with Higher-risk Early-stage Breast Cancer
Low-dose weekly administration of paclitaxel resulted in equal progression-free survival but reduced overall toxicity compared to every-2-week dose-dense administration for women with higher-risk early-stage breast cancer who have undergone surgery, according to a phase III randomized trial....
PTEN Variant Demonstrates Tumor Suppressor and Regression Activity in Human and Animal Tissue
A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. The variant, called PTEN-Long, may contribute to a cell’s healthy function and also...
Cytomegalovirus Might Speed Brain Cancer Growth
A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and Dana-Farber Cancer Institute suggests that cytomegalovirus, a virus that infects most adults in the United...
ASCO 2013: Adapting to Ongoing Shortages of Common Cancer Drugs
A survey of 214 U.S. oncologists and hematologists found that more than 80% encountered cancer drug shortages between March and September of 2012, and many reported that shortages affected the quality of patient care they were able to provide. As physicians were forced to substitute more expensive...
ASCO 2013: Cervical Cancer Screening Using Visual Inspection with Vinegar Reduces Mortality by 31% in Large Study in India
Cervical cancer mortality was reduced by 31% over a period of 15 years among women screened with biennial visual inspection with acetic acid (VIA), or vinegar, delivered by primary health workers in a large randomized study conducted among 150,000 women in India. The researchers estimate this...
ASCO 2013: 10 Years of Tamoxifen Better Than 5 in Reducing Breast Cancer Recurrence and Death
Ten years of adjuvant treatment with tamoxifen reduces breast cancer recurrence and mortality among women treated for early-stage estrogen receptor (ER)–positive breast cancer, according to results of the British phase III aTTom study. These findings, presented at the 2013 ASCO Annual Meeting ...
